The informative value of functional tests (with inderal, potassium and bicycle ergometer), the state of central hemodynamics, and the effectiveness of the anabolic hormone retabolil were studied in young females with dyshormonal myocardial dystrophy. The group consisted of 33 females between the ages of 33 and 45 with maintained menstrual cycle. The presence of cardialgia, syndrome of negative T wave, aggravated gynecologic anamnesis and the absence of clinical and laboratory data testifying to coronarogenous, inflammatory or some other lesion of the heart muscle made it possible to make the diagnosis of dyshormonal myocardial dystrophy. Functional tests with inderal and potassium and bicycle ergometry are objective criteria in the differential diagnosis of ischemic heart disease and dyshormonal myocardial dystrophy. Negative drug tests in individuals with persistent signs of dyshormonal dystrophy of the myocardium are evidence in favour of the development of postdystrophic cardiosclerosis. According to the data of hemodynamics, the functional state of the myocardium in patients with diffuse myocardial dystrophy is impaired. The anabolic hormone retabolil is an agent of pathogenetic therapy in the group of patients studied.
Injectable steroids are injected into muscle tissue, not into the veins. They are slowly released from the muscles into the rest of the body, and may be detectable for months after last use. Injectable steroids can be oil-based or water-based. Injectable anabolic steroids which are oil-based have longer half-life than water-based steroids. Both steroid types have much longer half-lives than oral anabolic steroids. And this is proving to be a drawback for injectables as they have high probability of being detected in drug screening since their clearance times tend to be longer than orals. Athletes resolve this problem by using injectable testosterone early in the cycle then switch to orals when approaching the end of the cycle and drug testing is imminent.